Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
64
XERS Quote, Financials, Valuation and Earnings
Last price:
$6.56
Seasonality move
:
1.07%
Day range:
$6.65 - $6.90
52-week range:
$3.14 - $10.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.03x
P/B ratio:
--
Volume:
1.4M
Avg. volume:
2.6M
1-year change:
88.24%
Market cap:
$1.1B
Revenue:
$203.1M
EPS (TTM):
-$0.10
Analysts' Opinion
-
Consensus RatingXeris Biopharma Holdings, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $11.50, Xeris Biopharma Holdings, Inc. has an estimated upside of 71.13% from its current price of $6.72.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $6.72.
Fair Value
-
According to the consensus of 5 analysts, Xeris Biopharma Holdings, Inc. has 71.13% upside to fair value with a price target of $11.50 per share.
XERS vs. S&P 500
-
Over the past 5 trading days, Xeris Biopharma Holdings, Inc. has underperformed the S&P 500 by -6.52% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Xeris Biopharma Holdings, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Xeris Biopharma Holdings, Inc. has grown year-over-year revenues for 24 quarters straight. In the most recent quarter Xeris Biopharma Holdings, Inc. reported revenues of $74.4M.
Earnings Growth
-
Xeris Biopharma Holdings, Inc. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Xeris Biopharma Holdings, Inc. reported earnings per share of $0.00.
Enterprise value:
1.3B
EV / Invested capital:
4.99x
Price / LTM sales:
4.03x
EV / EBIT:
130.69x
EV / Revenue:
4.81x
PEG ratio (5yr expected):
--
EV / Free cash flow:
128.43x
Price / Operating cash flow:
107.56x
Enterprise value / EBITDA:
57.11x
Gross Profit (TTM):
$214.2M
Return On Assets:
-4.68%
Net Income Margin (TTM):
-5.88%
Return On Equity:
-1019.2%
Return On Invested Capital:
-6.45%
Operating Margin:
9.05%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $152.7M | $187.4M | $266.1M | $54.3M | $74.4M | |
| Gross Profit | $114.5M | $141.6M | $214.2M | $38M | $60.7M | |
| Operating Income | -$49.3M | -$45.2M | $9.8M | -$12.9M | $6.7M | |
| EBITDA | -$35.9M | -$32.4M | $22.4M | -$9.8M | $9.9M | |
| Diluted EPS | -$0.45 | -$0.44 | -$0.10 | -$0.11 | $0.00 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $124.4M | $148.9M | $158.1M | $162.8M | $224M | |
| Total Assets | $131.3M | $303M | $327.8M | $321.1M | $370.2M | |
| Current Liabilities | $37.3M | $68.6M | $87M | $91M | $116.2M | |
| Total Liabilities | $133.7M | $248M | $323.9M | $349.4M | $371.1M | |
| Total Equity | -$2.5M | $55M | $3.9M | -$28.3M | -$861K | |
| Total Debt | $87.7M | $138.5M | $225.6M | $264.9M | $251.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$70.6M | -$32.7M | $10.6M | -$8.3M | $18.4M | |
| Cash From Investing | -$11.7M | $9.7M | $9.7M | $9.9M | -$71K | |
| Cash From Financing | $48.8M | $35.7M | $12.1M | -$83K | $13.9M | |
| Free Cash Flow | -$72.9M | -$33.5M | $10M | -$8.4M | $18.4M | |
XERS
Sector
Market Cap
$1.1B
$28.8M
Price % of 52-Week High
66.67%
51.13%
Dividend Yield
0%
0%
Shareholder Yield
-0.71%
-1.32%
1-Year Price Total Return
88.24%
-20.64%
Beta (5-Year)
0.667
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$6.92
200-day SMA
Buy
Level
$6.07
Bollinger Bands (100)
Sell
Level
6.24 - 8.76
Chaikin Money Flow
Sell
Level
-7.9M
20-day SMA
Sell
Level
$7.14
Relative Strength Index (RSI14)
Sell
Level
35.00
ADX Line
Sell
Level
23.35
Williams %R
Neutral
Level
-75.6786
50-day SMA
Sell
Level
$8.14
MACD (12, 26)
Buy
Level
1.41
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Sell
Level
-5.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.4858)
Sell
CA Score
(Annual)
Level (-3.2252)
Buy
Beneish M-Score
(Annual)
Level (-2.7516)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (5.1111)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (9)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Stock Forecast FAQ
In the current month, XERS has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The XERS average analyst price target in the past 3 months is $11.50.
-
Where Will Xeris Biopharma Holdings, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Xeris Biopharma Holdings, Inc. share price will rise to $11.50 per share over the next 12 months.
-
What Do Analysts Say About Xeris Biopharma Holdings, Inc.?
Analysts are divided on their view about Xeris Biopharma Holdings, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Xeris Biopharma Holdings, Inc. is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is Xeris Biopharma Holdings, Inc.'s Price Target?
The price target for Xeris Biopharma Holdings, Inc. over the next 1-year time period is forecast to be $11.50 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is XERS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Xeris Biopharma Holdings, Inc. is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of XERS?
You can purchase shares of Xeris Biopharma Holdings, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Xeris Biopharma Holdings, Inc. shares.
-
What Is The Xeris Biopharma Holdings, Inc. Share Price Today?
Xeris Biopharma Holdings, Inc. was last trading at $6.56 per share. This represents the most recent stock quote for Xeris Biopharma Holdings, Inc.. Yesterday, Xeris Biopharma Holdings, Inc. closed at $6.72 per share.
-
How To Buy Xeris Biopharma Holdings, Inc. Stock Online?
In order to purchase Xeris Biopharma Holdings, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get XERS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
XERS
Sector
P/E ratio
--
23.71x
PEG ratio
--
-0.01x
P/B ratio
--
1.84x
Price / LTM sales
4.03x
1.60x
Growth Metrics
XERS
Sector
Revenue growth
37.06%
4.85%
Earnings growth
103.31%
11.15%
Revenue (5-year growth)
136.89%
6.45%
Earnings forecast
$0.01
-$0.20
Profitability
XERS
Sector
Profitability FY 2024
$155.4M
$3.6M
Return on invested capital
-6.45%
-30.98%
Return on assets
-4.68%
-27.62%
Return on equity
-1019.2%
-36.69%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
5
Balance Sheet
XERS
Sector
Total cash
$91.6M
$27.2M
Short term investments
--
$25.7M
Total assets
$329.2M
$79.7M
Long term debt
$251.5M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 122.86% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 0.5% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is down 0.14% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
